Support: 888-992-3836
Copyright © 2023 InvestorsHub Inc.
Replies to post #4026 on Titan Pharmaceuticals Inc (TTNP)
TRUISM
12/12/14 6:50 PM
#4027 RE: matthewverymuch #4026
Doesn't stand for CAMurus?
Lund, Sweden and Princeton, New Jersey — November 20, 2014 — Camurus and Braeburn Pharmaceuticals announced today that they have entered into an exclusive license agreement for Camurus’ weekly and monthly subcutaneous buprenorphine injection products (CAM2038) for the treatment of opioid addiction and pain.
Braeburn’s pipeline now includes multiple long-acting implantable and injectable buprenorphine alternatives to oral formulations, ranging from one week to six months. These medications have the potential to change the treatment paradigms for opioid dependence and pain management, providing physicians with significant dosing flexibility to help meet the needs of each patient, and providing patients with greater freedom and peace of mind, allowing them to focus on other important aspects of their recovery.” said Behshad Sheldon, President and CEO, Braeburn Pharmaceuticals.